Asset
2X-121
Allarity Therapeutics Inc. Common Stock
Revenue
No revenue reported in loaded filings.
Clinical trials (2)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT03878849 | phase2 | recruiting | 2019-04-15 | 2027-03-01 | Allarity Therapeutics | Investigation of the Anti-tumor Effect of 2X-121 in Patients With Recurrent, Advanced Ovarian Cancer |
| NCT05571969 | phase1 | terminated | 2023-03-08 | 2024-02-19 | Allarity Therapeutics | Study of PARPi 2X-121 as Monotherapy and in Combination With Dovitinib in Patients With Advanced Solid Tumors |
FDA applications (0)
This company has no applications containing this asset.